Regeneron Pharma (REGN) PT Raised to $842 at H.C. Wainwright, Following Clinical Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Regeneron Pharma (REGN) PT Raised to $842 at H.C. Wainwright, Following Clinical Business Update

Regeneron (REGN) and Sanofi (SNY) Report Second Dupixent Phase 3 Trial Achieves Primary Endpoints Demonstrating Significant Disease Improvements

October 25, 2021 5:32 AM EDT

Regeneron (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) announce results from a second Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE) demonstrated that the trial met its co-primary endpoints in patients taking Dupixent 300 mg weekly, showing significant improvements in clinical (Dysphagia Symptom Questionnaire) and histologic disease measures compared to placebo. EoE is a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow. In September 2020, the U.S. Food and Drug Administration (FDA)... More